54. PREDICTION OF ANTIPSYCHOTIC-INDUCED METABOLIC ADVERSE EFFECTS USING MULTIMODAL ARTIFICIAL INTELLIGENCEKhushbu Agarwal, Ayman H. Fanous, Julie Kreyenbuhl et al.|European Neuropsychopharmacology|2024Cited by 1
F81. ELUCIDATING GENETIC AND ENVIRONMENTAL RISK FACTORS FOR ANTIPSYCHOTIC-INDUCED METABOLIC ADVERSE EFFECTS USING ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN THE MILLION VETERAN PROGRAMAyman H. Fanous, Beauty Kolade, Silviu‐Alin Bacanu et al.|European Neuropsychopharmacology|2023Cited by 0
89. PHARMACOGENOMICS AND PHARMACOTRANSCRIPTOMICS OF ANTIPSYCHOTIC-INDUCED HYPERCHOLESTEROLEMIA IN 58,000 VETERANSHamed Kazemi, Ayman H. Fanous, John H. Drake et al.|European Neuropsychopharmacology|2025Cited by 0
Genomic and transcriptomic insights into antipsychotic-induced changes in total cholesterol and body mass index in a multi-ancestry cohort of the US veteransHamed Kazemi, Ayman H. Fanous, John E. Drake et al.|medRxiv|2026Cited by 0